144 related articles for article (PubMed ID: 24326356)
1. HIV RNA levels in plasma and cervical-vaginal lavage fluid in elite controllers and HAART recipients.
Landay A; Golub ET; Desai S; Zhang J; Winkelman V; Anastos K; Durkin H; Young M; Villacres MC; Greenblatt RM; Norris PJ; Busch MP;
AIDS; 2014 Mar; 28(5):739-43. PubMed ID: 24326356
[TBL] [Abstract][Full Text] [Related]
2. Association between paired plasma and cervicovaginal lavage fluid HIV-1 RNA levels during 36 months.
Cu-Uvin S; Snyder B; Harwell JI; Hogan J; Chibwesha C; Hanley D; Ingersoll J; Kurpewski J; Mayer KH; Caliendo AM
J Acquir Immune Defic Syndr; 2006 Aug; 42(5):584-7. PubMed ID: 16837866
[TBL] [Abstract][Full Text] [Related]
3. Plasma and mucosal HIV viral loads are associated with genital tract inflammation in HIV-infected women.
Herold BC; Keller MJ; Shi Q; Hoover DR; Carpenter CA; Huber A; Parikh UM; Agnew KJ; Minkoff H; Colie C; Nowicki MJ; DʼSouza G; Watts DH; Anastos K
J Acquir Immune Defic Syndr; 2013 Aug; 63(4):485-93. PubMed ID: 23591635
[TBL] [Abstract][Full Text] [Related]
4. Evidence for innate immune system activation in HIV type 1-infected elite controllers.
Krishnan S; Wilson EM; Sheikh V; Rupert A; Mendoza D; Yang J; Lempicki R; Migueles SA; Sereti I
J Infect Dis; 2014 Mar; 209(6):931-9. PubMed ID: 24185941
[TBL] [Abstract][Full Text] [Related]
5. HIV-DNA in the genital tract of women on long-term effective therapy is associated to residual viremia and previous AIDS-defining illnesses.
Prazuck T; Chaillon A; Avettand-Fènoël V; Caplan AL; Sayang C; Guigon A; Niang M; Barin F; Rouzioux C; Hocqueloux L
PLoS One; 2013; 8(8):e69686. PubMed ID: 23990886
[TBL] [Abstract][Full Text] [Related]
6. Presence of hepatitis C virus (HCV) RNA in the genital tracts of HCV/HIV-1-coinfected women.
Nowicki MJ; Laskus T; Nikolopoulou G; Radkowski M; Wilkinson J; Du WB; Rakela J; Kovacs A
J Infect Dis; 2005 Nov; 192(9):1557-65. PubMed ID: 16206070
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal effect following initiation of highly active antiretroviral therapy on plasma and cervico-vaginal HIV-1 RNA among women in Burkina Faso.
Nagot N; Ouedraogo A; Weiss HA; Konate I; Sanon A; Defer MC; Sawadogo A; Andonaba JB; Vallo R; Becquart P; Segondy M; Mayaud P; Van de Perre P;
Sex Transm Infect; 2008 Jun; 84(3):167-70. PubMed ID: 18055582
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Performance Characteristics of the Aptima HIV-1 Quant Dx Assay for Detection and Quantitation of Human Immunodeficiency Virus Type 1 in Plasma and Cervicovaginal Lavage Samples.
Sam SS; Kurpewski JR; Cu-Uvin S; Caliendo AM
J Clin Microbiol; 2016 Apr; 54(4):1036-41. PubMed ID: 26842702
[TBL] [Abstract][Full Text] [Related]
9. Transient relapses ("blips") of plasma HIV RNA levels during HAART are associated with drug resistance.
Cohen Stuart JW; Wensing AM; Kovacs C; Righart M; de Jong D; Kaye S; Schuurman R; Visser CJ; Boucher CA
J Acquir Immune Defic Syndr; 2001 Oct; 28(2):105-13. PubMed ID: 11588503
[TBL] [Abstract][Full Text] [Related]
10. HIV+ elite controllers have low HIV-specific T-cell activation yet maintain strong, polyfunctional T-cell responses.
Owen RE; Heitman JW; Hirschkorn DF; Lanteri MC; Biswas HH; Martin JN; Krone MR; Deeks SG; Norris PJ;
AIDS; 2010 May; 24(8):1095-105. PubMed ID: 20400885
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy.
Hermankova M; Ray SC; Ruff C; Powell-Davis M; Ingersoll R; D'Aquila RT; Quinn TC; Siliciano JD; Siliciano RF; Persaud D
JAMA; 2001 Jul; 286(2):196-207. PubMed ID: 11448283
[TBL] [Abstract][Full Text] [Related]
12. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA.
Cu-Uvin S; Caliendo AM; Reinert S; Chang A; Juliano-Remollino C; Flanigan TP; Mayer KH; Carpenter CC
AIDS; 2000 Mar; 14(4):415-21. PubMed ID: 10770544
[TBL] [Abstract][Full Text] [Related]
13. Virological characterization of patients treated early is able to control HIV-1 replication after multiple cycles of structured therapy interruption.
Rozera G; Abbate I; D'Offizi G; Corpolongo A; Narciso P; Vlassi C; Martini F; Calcaterra S; Capobianchi MR
J Med Virol; 2007 Aug; 79(8):1047-54. PubMed ID: 17597482
[TBL] [Abstract][Full Text] [Related]
14. Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: a cross-sectional evaluation.
Bonora S; Nicastri E; Calcagno A; Gonzalez de Requena D; D'Ettorre G; Sarmati L; Palmisano L; Vullo V; Di Perri G; Andreoni M
J Med Virol; 2009 Mar; 81(3):400-5. PubMed ID: 19152404
[TBL] [Abstract][Full Text] [Related]
15. Control of HIV-1 RNA load after HAART interruption: relationship with CCR5 co-receptor density and proviral DNA load in HIV-infected patients.
Soriano-Sarabia N; Vallejo A; Fernández G; Genebat M; Gutiérrez S; Muñoz-Fernández MA; Leal M
J Clin Virol; 2007 Sep; 40(1):64-7. PubMed ID: 17662650
[TBL] [Abstract][Full Text] [Related]
16. Persistent low viral load on antiretroviral therapy is associated with T cell-mediated control of HIV replication.
Alatrakchi N; Duvivier C; Costagliola D; Samri A; Marcelin AG; Kamkamidze G; Astriti M; Agher R; Calvez V; Autran B; Katlama C
AIDS; 2005 Jan; 19(1):25-33. PubMed ID: 15627030
[TBL] [Abstract][Full Text] [Related]
17. Highly divergent patterns of genetic diversity and evolution in proviral quasispecies from HIV controllers.
de Azevedo SSD; Caetano DG; Côrtes FH; Teixeira SLM; Dos Santos Silva K; Hoagland B; Grinsztejn B; Veloso VG; Morgado MG; Bello G
Retrovirology; 2017 May; 14(1):29. PubMed ID: 28464889
[TBL] [Abstract][Full Text] [Related]
18. HIV controllers with different viral load cutoff levels have distinct virologic and immunologic profiles.
Côrtes FH; Passaes CP; Bello G; Teixeira SL; Vorsatz C; Babic D; Sharkey M; Grinsztejn B; Veloso V; Stevenson M; Morgado MG
J Acquir Immune Defic Syndr; 2015 Apr; 68(4):377-385. PubMed ID: 25564106
[TBL] [Abstract][Full Text] [Related]
19. Infrequent recovery of HIV from but robust exogenous infection of activated CD4(+) T cells in HIV elite controllers.
Julg B; Pereyra F; Buzón MJ; Piechocka-Trocha A; Clark MJ; Baker BM; Lian J; Miura T; Martinez-Picado J; Addo MM; Walker BD
Clin Infect Dis; 2010 Jul; 51(2):233-8. PubMed ID: 20550452
[TBL] [Abstract][Full Text] [Related]
20. Transcriptional profiling of CD4 T cells identifies distinct subgroups of HIV-1 elite controllers.
Vigneault F; Woods M; Buzon MJ; Li C; Pereyra F; Crosby SD; Rychert J; Church G; Martinez-Picado J; Rosenberg ES; Telenti A; Yu XG; Lichterfeld M
J Virol; 2011 Mar; 85(6):3015-9. PubMed ID: 21177805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
